Health ❯ Healthcare ❯ Pharmaceuticals

Cancer Treatment

Breast Cancer Immunotherapy Clinical Trials Drug Development Small Cell Lung Cancer Lung Cancer Multiple Myeloma Bladder Cancer Targeted Therapy Prostate Cancer Oncology Keytruda Non-Small Cell Lung Cancer Gene Therapy Life-saving Drugs Medication Supply Existing Drugs Ogsiveo 3SBio Licensing Deal Drug Pricing Tyrosine Kinase Inhibitors Chemotherapy Pembrolizumab Triple-Negative Breast Cancer Trastuzumab Deruxtecan Opdivo Monoclonal Antibodies Cutaneous Squamous Cell Carcinoma Libtayo PARP Inhibitors Amtagvi Colorectal Cancer Acute Myeloid Leukemia Oncology Research Basal Cell Carcinoma Menin Inhibitors Gastrointestinal Cancer mRNA Technology mRNA Therapies mRNA Therapy Radiation Therapy Springworks Therapeutics

Merck Beats in Q3 on Keytruda, Narrows 2025 Outlook as Gardasil Slumps in China

Guidance reflects lower expected tariff costs.

FDA Expands Revumenib Approval to NPM1-Mutant Relapsed/Refractory AML in Patients 1 and Older

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC